Navigation Links
Red wine compound increases anti-tumor effect of rapamycin
Date:2/14/2011

Monday, February 14, 2011 Cleveland Researchers from Cleveland Clinic's Lerner Research Institute have discovered that resveratrol a compound found in red wine when combined with rapamycin can have a tumor-suppressing effect on breast cancer cells that are resistant to rapamycin alone.

The research recently published in Cancer Letters also indicates that the PTEN tumor-suppressing gene contributes to resveratrol's anti-tumor effects in this treatment combination.

Charis Eng, MD, Ph.D., Chair of the Genomic Medicine Institute of Cleveland Clinic's Lerner Research Institute, led her team to study the effect of combining resveratrol, a chemopreventive drug found in many natural compounds, with rapamycin on breast cancer cells. The research demonstrates an additive effect between these two drugs on breast cancer cell signaling and growth.

"Rapamycin has been used in clinical trials as a cancer treatment. Unfortunately, after a while, the cancer cells develop resistance to rapamycin," Eng said. "Our findings show that resveratrol seems to mitigate rapamycin-induced drug resistance in breast cancers, at least in the laboratory. If these observations hold true in the clinic setting, then enjoying a glass of red wine or eating a bowl of boiled peanuts which has a higher resveratrol content than red wine before rapamycin treatment for cancer might be a prudent approach."

Rapamycin, an immunosuppressant drug used to prevent rejection in organ transplantation, has been considered for the use of anti-tumor activity against breast cancer. Resveratrol is a type of polyphenol that is found in the skin of red grapes and is a constituent of red wine, and has been considered for multiple uses regarding cellular therapies.

Despite the potential for tumor suppression, rapamycin's efficacy with respect to growth inhibition differs markedly among various breast cancer cell lines. The effect of resveratrol and rapamycin, alone and in combination, on cell growth of three human breast cancer cell lines was assessed. Rapamycin, resveratrol, and combinations of these agents inhibited cell growth in a dose-dependent manner. In all three cell lines tested, the presence of low concentrations of resveratrol and rapamycin was sufficient to induce 50 percent growth inhibition. Although relatively early, these observations may suggest resveratrol as a powerful integrative medicine adjunct to traditional chemotherapy.


'/>"/>

Contact: Dan Doron
dorond@ccf.org
216-312-0428
Lerner Research Institute
Source:Eurekalert

Related medicine news :

1. Compound shows promise against intractable heart failure
2. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
3. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
4. New pyrimidine compounds may lead to improved treatments for childhood brain cancer
5. Researchers find compound effective in destroying antibiotic-resistant biofilms
6. Compound enhances cancer-killing properties of agent in trials
7. Concentration, timing and interactions are key when it comes to dietary compounds
8. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
9. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
10. Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens
11. New investigational compound targets pancreatic cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 02, 2016 , ... "Pro3rd Accents Volume 2 is a set of 30 ... titles with just a few clicks of the mouse," said Christina Austin - CEO ... animations. Choose from various styles with accented animations, rigid boxes, simplistic lines, and more. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... to build intelligent, connected applications, was named the best Sales Team of 2016 ... winner announcement was made today by the Software & Information Industry Association (SIIA), ...
(Date:11/30/2016)... Boston, Massachusetts (PRWEB) , ... November 30, 2016 ... ... is proud to announce that we have been designated as a Cigna Infertility ... meet or exceed rigorous performance standards. , “It’s an honor to be ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard Process, Inc. is proud ... and recognition of the largest closely held companies headquartered in Wisconsin. This marks ... addition, Standard Process was awarded the Talent Award for providing outstanding employee benefits. ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... treating injured workers have been a focus of public policymakers and system stakeholders ... Research Institute (WCRI) released its Medical Price Index for Workers’ Compensation, Eighth ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of the "R&D ... ... R&D Drug Pipeline Database: 1-Year Subscription Subscription ... online access to information about more than 21,000 project entries (files) ... in research & development. Pre-established and free search ...
(Date:12/2/2016)... SPRING, Md. , Dec. 2, 2016 ... new indication for Jardiance (empagliflozin) to reduce the risk ... diabetes mellitus and cardiovascular disease. "Cardiovascular ... with type 2 diabetes mellitus," said Jean-Marc Guettier ... and Endocrinology Products in FDA,s Center for Drug Evaluation ...
(Date:12/2/2016)... Columbia , December 2, 2016 - bioLytical lanza el ... nuevas directrices de la OMS     Continue Reading ... ... , , ... enfermedades infecciosas, ha anunciado hoy que está expandiendo el lanzamiento de su INSTI ...
Breaking Medicine Technology: